@article {Bodger1092, author = {Keith Bodger and Clare Ormerod and Daniela Shackcloth and Melanie Harrison and on behalf of the IBD Control Collaborative}, editor = {Ahmed, Suhail and Bowering, Katherine and Brown, Elizabeth and Hurst, Anne and Gledhill, Tamsin}, title = {Development and validation of a rapid, generic measure of disease control from the patient{\textquoteright}s perspective: the IBD-Control questionnaire}, volume = {63}, number = {7}, pages = {1092--1102}, year = {2014}, doi = {10.1136/gutjnl-2013-305600}, publisher = {BMJ Publishing Group}, abstract = {Introduction The use of patient reported outcome measures to support routine inflammatory bowel disease (IBD) care is not widespread and suggests that existing questionnaires lack relevance to day-to-day decisions or are too cumbersome to administer. We developed a simple, generic tool for capturing disease control from the patient{\textquoteright}s perspective to address these barriers. Methods Development based on literature review, patient focus groups/interviews and a steering group, defining a limited set of generic questions. The {\textquoteleft}IBD-Control{\textquoteright} questionnaire comprises 13 items plus a visual analogue scale (VAS) (0{\textendash}100). Prospective validation involved baseline completion of IBD-Control, quality of life (QoL) questionnaire (UK-IBD-Q), EuroQol (EQ-5D), Hospital Anxiety and Depression Score; and clinician assessment (blinded to questionnaire; recording Harvey-Bradshaw Index or Simple Clinical Colitis Activity Index; Global Clinician Rating; treatment outcome). Results 299 patients returned baseline surveys (Crohn{\textquoteright}s disease, n=160; ulcerative colitis, n=139) and 138 attended for repeat visits. Completion time (mean; SD): 1 min 15 s; 25 s; Internal consistency: Cronbach{\textquoteright}s α for all 13 items (0.85); for subgroup of eight questions ({\textquoteleft}IBD-Control-8{\textquoteright}; 0.86). Strong correlation between IBD-Control-8 and IBD-Control-VAS (r=0.81). Test-retest reliability (2 week repeat): intra-class correlation=0.97 for IBD-Control-8 and 0.96 for IBD-Control-VAS. Construct validity: Moderate-to-strong correlations between IBD-Control-8 and IBD-Control-VAS versus activity indices, UK-IBD-Q and EQ-5D (utility) with r values 0.52{\textendash}0.86. Discriminant validity (mean instrument scores for remission, mild, moderate or severe): p\<0.001 (analysis of variance (ANOVA)). Sensitivity to change: Effect sizes: 0.76{\textendash}1.44. Conclusions The IBD-Control is a rapid, reliable, valid and sensitive instrument for measuring overall disease control from the patient{\textquoteright}s perspective. Unlike existing patient reported outcome measures, its simplicity, ease-of-use and generic applicability make it a candidate for supporting routine care.}, issn = {0017-5749}, URL = {https://gut.bmj.com/content/63/7/1092}, eprint = {https://gut.bmj.com/content/63/7/1092.full.pdf}, journal = {Gut} }